Publikation

Publikationsliste
Publikationen mit Beteiligung von Mitgliedern der MPGN-Arbeitsgruppe:
Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF,
Silvestri G, Skerka C, Józsi M, Zipfel PF, Hageman GS, Smith RJ. Variations in the
complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are
associated with membranoproliferative glomerulonephritis type II (dense deposit
disease). J Med Genet. 2006 Jul;43(7):582-9.
Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M,
Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ,
Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Würzner R, Zipfel PF.
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.
J Am Soc Nephrol. 2005 May;16(5):1392-403.
Benz K, Amann K. Pathological aspects of membranoproliferative
glomerulonephritis (MPGN) and haemolytic uraemic syndrome (HUS) / thrombocytic
thrombopenic purpura (TTP). Thromb Haemost 2009 Feb;101(2):265-70.
Chen Q, Müller D, Rudolph B, Hartmann A, Kuwertz-Bröking E, Wu K, Kirschfink M,
Skerka C, Zipfel PF. Combined C3b and factor B autoantibodies and MPGN type
II.N Engl J Med. 2011 Dec 15;365(24):2340-2.
De S, Al-Nabhani D, Thorner P, Cattran D, Piscione TD, Licht C. Remission of
resistant MPGN type I with mycophenolate mofetil and steroids. Pediatr Nephrol.
2009 Mar;24(3):597-600.
Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, Kirschfink M,
Hoppe B, Zipfel PF, Licht C. C3 deposition glomerulopathy due to a functional
factor H defect. Kidney Int. 2009 Jun;75(11):1230-4.
Licht C, Fremeaux-Bacchi V. Hereditary and acquired complement dysregulation in
membranoproliferative glomerulonephritis. Thromb Haemost. 2009 Feb;101(2):271-
8. (Review)
Licht C, Schlötzer-Schrehardt U, Kirschfink M, Zipfel PF, Hoppe B. MPGN II--
genetically determined by defective complement regulation? Pediatr Nephrol. 2007
Jan;22(1):2-9.
Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, Pluthero
F, Licht C. Eculizumab and refractory membranoproliferative glomerulonephritis. N
Engl J Med. 2012 Mar 22;366(12):1165-6. No abstract available.
Schwertz R, Rother U, Anders D, Gretz N, Scharer K, Kirschfink M. Complement
analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-
term follow-up. Pediatr Allergy Immunol 2001 Jun;12(3):166-72.
Sethi S, Gamez JD, Vrana JA, Theis JD, Bergen HR 3rd, Zipfel PF, Dogan A, Smith
RJ. Glomeruli of Dense Deposit Disease contain components of the alternative and
terminal complement pathway. Kidney Int. 2009 May;75(9):952-60.
Skerka C, Licht C, Mengel M, Uzonyi B, Strobel S, Zipfel PF, Józsi M. Autoimmune
forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis:
Indications for a disease spectrum and common pathogenic principles. Mol Immunol.
2009 Sep;46(14):2801-7.
Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Córdoba
SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis
V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S,
Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, Würzner R, Zipfel PF;
Dense Deposit Disease Focus Group. New approaches to the treatment of dense
deposit disease. J Am Soc Nephrol. 2007 Sep;18(9):2447-56.

Source: http://www.mpgn-registry.de/images/publikation1.pdf